Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in EGFR-amplified Refractory Solid Tumors
NCT02447419Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Dec 2014
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in solid tumor, sponsored by Samsung Medical Center. Started Dec 2014; status: completed.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02447419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447419.